

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2877)

TURNOVER FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2021

The board of directors (the “Board”) of China Shineway Pharmaceutical Group Limited (the “Company”) is pleased to announce that, the turnover of the Company and its subsidiaries (together, the “Group”) for the nine months ended 30 September 2021 based on its management accounts which have not been reviewed by the auditors, was RMB 2,337 million, representing an increase of 24.3% as compared with the same period of 2020, and in particular:

- Turnover of injection products increased by 23.4% to RMB 971 million;
- Turnover of soft capsule products increased by 9.0% to RMB 385 million;
- Turnover of granule products increased by 47.9% to RMB 355 million;
- Turnover of TCM formula granule products increased by 22.2% to RMB 501 million; and
- Turnover of products in other forms increased by 38.8% to RMB 125 million.

In terms of product mix, injection products, soft capsule products, granule products and TCM formula granule products accounted for approximately 41.6%, 16.5%, 15.2% and 21.4% of the total turnover respectively for the nine months ended 30 September 2021.

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board
China Shineway Pharmaceutical Group Limited
Li Zhenjiang
Chairman

Hong Kong, 8 November 2021

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; the non-executive director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Liu Shun Fai.